Charles R. Drew University of Medicine and Science
Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003 May-Jun; 9(3):237-52.
American College of Endocrinology position statement on the insulin resistance syndrome.
Lebovitz HE, Austin MM, Blonde L, Davidson JA, Del Prato S, Gavin JR, Handelsman Y, Jellinger PS, Levy P, Riddle MC, Roberts VL, Siminerio LM, ACE/AACE Diabetes Recommendations Implementation Writing Committee
ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract. 2006 Jan-Feb; 12 Suppl 1:6-12.
ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations.
Jellinger PS, Davidson JA, Blonde L, Einhorn D, Grunberger G, Handelsman Y, Hellman R, Lebovitz H, Levy P, Roberts VL, ACE/AACE Diabetes Road Map Task Force
Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007 May-Jun; 13(3):260-8.
Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force.
Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F, AACE Diabetes Mellitus Clinical Practice Guidelines Task Force
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007 May-Jun; 13 Suppl 1:1-68.
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus.
Metabolic syndrome and related disorders
Guest editorial. Metab Syndr Relat Disord. 2005; 3(4):281-3.
Nature clinical practice. Endocrinology & metabolism
Pharmacologic treatment options for prediabetes. Nat Clin Pract Endocrinol Metab. 2008 Jul; 4(7):380-1.
Pharmacologic treatment options for prediabetes.
Treating diabetes with incretin hormones - clinical experience. Pediatr Endocrinol Rev. 2008 Jun; 5(4):897-903.
Treating diabetes with incretin hormones - clinical experience.
The use of the bile acid sequestrant colesevelam HCl in patients with type 2 diabetes mellitus: for glucose and lipid control. Introduction. Postgrad Med. 2009 May; 121(3 Suppl 1):5-6.
The use of the bile acid sequestrant colesevelam HCl in patients with type 2 diabetes mellitus: for glucose and lipid control. Introduction.
The role of colesevelam HCl in type 2 diabetes mellitus therapy. Postgrad Med. 2009 May; 121(3 Suppl 1):19-24.
The role of colesevelam HCl in type 2 diabetes mellitus therapy.
Handelsman Y, Abby SL, Jin X, Donovan JM, Jones MR
Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes. Postgrad Med. 2009 Nov; 121(6):62-9.
Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes.
Cancer mortality and insulin glargine. J Diabetes. 2009 Sep; 1(3):131-3.
Bloomgarden ZT, Ning G, Drexler AJ, Guan YF, Handelsman Y, Li XY, Liu JM
Good news! J Diabetes. 2010 Sep; 2(3):127.
Zhang Y, Ning G, Handelsman Y, Bloomgarden ZT
Gut hormones and the brain. J Diabetes. 2010 Sep; 2(3):138-45.
Insulin treatment of Type 2 diabetes: a clinical perspective. J Diabetes. 2010 Jun; 2(2):65-6.
Insulin treatment of Type 2 diabetes: a clinical perspective.
The Avandia debate: an unhappy conclusion. J Diabetes. 2010 Dec; 2(4):221-2.
The Avandia debate: an unhappy conclusion.
Ford ES, Cowie CC, Li C, Handelsman Y, Bloomgarden ZT
Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2011 Mar; 3(1):67-73.
Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US.
The role of bile acid sequestrants in the management of type 2 diabetes mellitus: summary and future directions. Metab Syndr Relat Disord. 2010 Dec; 8 Suppl 1:S23-4.
The role of bile acid sequestrants in the management of type 2 diabetes mellitus: summary and future directions.
Grunberger G, Bailey TS, Cohen AJ, Flood TM, Handelsman Y, Hellman R, Jovanovic L, Moghissi ES, Orzeck EA, AACE Insulin Pump Management Task Force
Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. Endocr Pract. 2010 Sep-Oct; 16(5):746-62.
Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management.
Journal of clinical hypertension (Greenwich, Conn.)
Diabetes and hypertension: a comprehensive report on management and the prevention of cardiovascular and renal complications. J Clin Hypertens (Greenwich). 2011 Apr; 13(4):221-3.
Diabetes and hypertension: a comprehensive report on management and the prevention of cardiovascular and renal complications.
Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanovic L, Lebovitz H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL, AACE Task Force for Developing Diabetes Comprehensive Care Plan
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011 Mar-Apr; 17 Suppl 2:1-53.
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan.
Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanovic L, Lebovitz H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL, AACE Task Force for Developing a Diabetes Comprehensive Care Plan
American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract. 2011 Mar-Apr; 17(2):287-302.
American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary.
Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. J Diabetes. 2011 Dec; 3(4):257-60.
Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids.
Did AIM-HIGH aim too low? J Diabetes. 2012 Mar; 4(1):1-2.
Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus? Expert Rev Clin Pharmacol. 2012 Jan; 5(1):43-54.
Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?
Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA, AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012 Mar-Apr; 18 Suppl 1:1-78.
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis.
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH, American Association of Clinical Endocrinologists
AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
AACE comprehensive diabetes management algorithm 2013.
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE, Davidson MH
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract. 2013 May-Jun; 19(3):536-57.
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.
Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, Rana A, Zinman B, BEGIN: VICTOZA ADD-ON (NN1250-3948) study group
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014 Jul; 16(7):636-44.
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
Rodbard HW, Cariou B, Zinman B, Handelsman Y, Wolden ML, Rana A, Mathieu C
Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-na?ve patients with type 2 diabetes. Diabetes Obes Metab. 2014 Sep; 16(9):869-72.
Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-na?ve patients with type 2 diabetes.
Leiter LA, Carr MC, Stewart M, Jones-Leone A, Scott R, Yang F, Handelsman Y
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014 Oct; 37(10):2723-30.
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovic L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F
American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015 Apr; 21 Suppl 1:1-87.
American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015.
Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Despr?s JP, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MR, Blum QK, Collins KK, Cook S, Dhurandhar NV, Dixon DL, Egan BM, Ferdinand DP, Herman LM, Hessen SE, Jacobson TA, Pate RR, Ratner RE, Brinton EA, Forker AD, Ritzenthaler LL, Grundy SM
Journal of the American College of Cardiology
The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol. 2015 Sep 01; 66(9):1050-67.
The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome.
Approaches to treatment 2: Comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines. J Diabetes. 2016 Jan; 8(1):4-6.
Approaches to treatment 2: Comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines.
Bailey TS, Grunberger G, Bode BW, Handelsman Y, Hirsch IB, Jovanovic L, Roberts VL, Rodbard D, Tamborlane WV, Walsh J, American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2016 OUTPATIENT GLUCOSE MONITORING CONSENSUS STATEMENT. Endocr Pract. 2016 Feb; 22(2):231-61.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2016 OUTPATIENT GLUCOSE MONITORING CONSENSUS STATEMENT.
Fonseca VA, Grunberger G, Anhalt H, Bailey TS, Blevins T, Garg SK, Handelsman Y, Hirsch IB, Orzeck EA, Roberts VL, Tamborlane W, Consensus Conference Writing Committee
CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016 Aug; 22(8):1008-21.
CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. Endocr Pract. 2015 Apr; 21(4):413-37.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY.
Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, Segal RL, Garber JR, Hamilton CR, Handelsman Y, Hellman R, Kukora JS, Levy P, Palumbo PJ, Petak SM, Rettinger HI, Rodbard HW, Service FJ, Shankar TP, Stoffer SS, Tourtelot JB
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE EVALUATION AND TREATMENT OF HYPERTHYROIDISM AND HYPOTHYROIDISM. Endocr Pract. 2002 Nov; 8(6):457-469.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE EVALUATION AND TREATMENT OF HYPERTHYROIDISM AND HYPOTHYROIDISM.
Sanon VP, Handelsman Y, Pham SV, Chilton R
Clinical diabetes : a publication of the American Diabetes Association
Cardiac Manifestations of Congenital Generalized Lipodystrophy. Clin Diabetes. 2016 Oct; 34(4):181-186.
Cardiac Manifestations of Congenital Generalized Lipodystrophy.
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS. Endocr Pract. 2017 Jan; 23(1):100-112.
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Linjawi S, Bode BW, Chaykin LB, Courr?ges JP, Handelsman Y, Lehmann LM, Mishra A, Simpson RW
Diabetes therapy : research, treatment and education of diabetes and related disorders
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Ther. 2017 Feb; 8(1):101-114.
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.
Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop PH, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JP, Ratner RE
Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017 02; 66(2):241-255.
Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. Endocr Pract. 2017 02; 23(2):207-238.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr; 23(Suppl 2):1-87.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Brown WV, Handelsman Y, Martin SS, Morris PB
JCL roundtable: Future of the lipid laboratory: Choosing valuable measures among the lipoproteins (part 1). J Clin Lipidol. 2017 May - Jun; 11(3):587-595.
JCL roundtable: Future of the lipid laboratory: Choosing valuable measures among the lipoproteins (part 1).
Handelsman Y, Lauring B, Gantz I, Iredale C, O'Neill EA, Wei Z, Suryawanshi S, Kaufman KD, Engel SS, Lai E
A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017 10; 33(10):1861-1868.
A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 12; 5(12):941-950.
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Response to Comment on Bloomgarden et al. Is HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old? Diabetes Care 2017;40:526-528. Diabetes Care. 2017 10; 40(10):e154.
Response to Comment on Bloomgarden et al. Is HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old? Diabetes Care 2017;40:526-528.
How does CKD affect HbA1c? J Diabetes. 2018 Apr; 10(4):270.
Fonseca VA, Bloomgarden ZT, Dagogo-Jack S, Grunberger G, Einhorn D, Garber AJ, Handelsman Y, Hirsch IB, Umpierrez GE
AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES. Endocr Pract. 2017 Nov; 23(11):1345-1349.
AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES.
Transition from hospital to outpatient diabetes care. J Diabetes. 2018 Jul; 10(7):538-540.
Transition from hospital to outpatient diabetes care.
Bloomgarden Z, Einhorn D, Handelsman Y, Misra A, Zonszein J, Grunberger G, Jellinger PS, Garber AJ
American College of Physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia. J Diabetes. 2018 Aug; 10(8):618-620.
American College of Physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia.
Cannon A, Handelsman Y, Heile M, Shannon M
Journal of managed care & specialty pharmacy
Burden of Illness in Type 2 Diabetes Mellitus. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S5-S13.
Burden of Illness in Type 2 Diabetes Mellitus.
Handelsman Y, Wyne K, Cannon A, Shannon M, Schneider D
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S14-S29.
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists.
Heile M, Wyne K, Billings LK, Cannon A, Handelsman Y, Shannon M
Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S42-S52.
Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications.
Billings LK, Handelsman Y, Heile M, Schneider D, Wyne K
Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S30-S41.
Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus.
Li S, Peng Y, Wang X, Qian Y, Xiang P, Wade SW, Guo H, Lopez JAG, Herzog CA, Handelsman Y
Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019 Mar; 42(3):391-399.
Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. Endocr Pract. 2019 01; 25(1):69-100.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Mechanick JI, Garber AJ, Grunberger G, Handelsman Y, Garvey WT
DYSGLYCEMIA-BASED CHRONIC DISEASE: AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT. Endocr Pract. 2018 Nov; 24(11):995-1011.
DYSGLYCEMIA-BASED CHRONIC DISEASE: AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT.
Corrections. J Manag Care Spec Pharm. 2018 Nov; 24(11):1196a.
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther. 2019 10; 36(10):2567-2586.
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication. J Diabetes. 2020 Jan; 12(1):8-9.
Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication.
Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. Adv Ther. 2020 Feb; 37(2):973.
Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.
Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, Davidson MH, Einhorn D, Fazio S, Fonseca VA, Garber AJ, Grunberger G, Krauss RM, Mechanick JI, Rosenblit PD, Smith DA, Wyne KL
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary.
Grunberger G, Sherr J, Allende M, Blevins T, Bode B, Handelsman Y, Hellman R, Lajara R, Roberts VL, Rodbard D, Stec C, Unger J
American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. Endocr Pract. 2021 06; 27(6):505-537.
American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus.
Handelsman Y, Bunch TJ, Rodbard HW, Steinberg BA, Thind M, Bigot G, Konigsberg L, Wieloch M, Kowey PR
Journal of diabetes and its complications
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies. J Diabetes Complications. 2022 07; 36(7):108227.
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
DeFronzo RA, Auchus RJ, Bancos I, Blonde L, Busch RS, Buse JB, Findling JW, Fonseca VA, Frias JP, Hamidi O, Handelsman Y, Pratley RE, Rosenstock J, Tudor IC, Moraitis AG, Einhorn D
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone. BMJ Open. 2024 07 16; 14(7):e081121.
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone.
Diabetes, cardiorenal, and metabolic multispecialty practice recommendations and early intensive management of cardio-renal-metabolic disease. Am J Manag Care. 2024 Dec; 30(10 Suppl):S189-S196.
Diabetes, cardiorenal, and metabolic multispecialty practice recommendations and early intensive management of cardio-renal-metabolic disease.
Masson W, Barbagelata L, Lobo M, Nogueira JP, Handelsman Y
Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis. J Clin Lipidol. 2025 May-Jun; 19(3):412-421.
Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis.
Treatment of the insulin resistance syndrome. Endocr Pract. 2003 Sep-Oct; 9 Suppl 2:99-104.
Treatment of the insulin resistance syndrome.
Mechanick JI, Handelsman Y, Bloomgarden ZT
Current opinion in clinical nutrition and metabolic care
Hypoglycemia in the intensive care unit. Curr Opin Clin Nutr Metab Care. 2007 Mar; 10(2):193-6.
Hypoglycemia in the intensive care unit.
Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, Garvey WT, Gavin JR, Grunberger G, Horton ES, Jellinger PS, Jones KL, Lebovitz H, Levy P, McGuire DK, Moghissi ES, Nesto RW
Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008 Oct; 14(7):933-46.
Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists.
Metabolic syndrome pathophysiology and clinical presentation. Toxicol Pathol. 2009 Jan; 37(1):18-20.
Metabolic syndrome pathophysiology and clinical presentation.
Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR
Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract. 2010 Jan-Feb; 16(1):53-63.
Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009 Sep-Oct; 15(6):540-59.
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010 May; 12(5):384-92.
Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.
Bile acid sequestrants for lipid and glucose control. Curr Diab Rep. 2010 Feb; 10(1):70-7.
Bile acid sequestrants for lipid and glucose control.
Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, Lai YL, Jin X, Misir S, Nagendran S, Jones MR
Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug; 16(4):629-40.
Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes.
Handelsman Y, Goldberg RB, Garvey WT, Fonseca VA, Rosenstock J, Jones MR, Lai YL, Jin X, Misir S, Nagendran S, Abby SL
Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract. 2010 Jul-Aug; 16(4):617-28.
Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study.
Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care. 2011 May; 34 Suppl 2:S244-50.
Role of bile acid sequestrants in the treatment of type 2 diabetes.
Diabetes in youth: a dilemma of pathogenesis. J Diabetes. 2011 Jun; 3(2):91-2.
Diabetes in youth: a dilemma of pathogenesis.
Overcoming obstacles in risk factor management in type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2011 Aug; 13(8):613-20.
Overcoming obstacles in risk factor management in type 2 diabetes mellitus.
Effectiveness of primary care-relevant treatments for obesity in adults. Ann Intern Med. 2012 Feb 07; 156(3):248-9; author reply 249.
Effectiveness of primary care-relevant treatments for obesity in adults.
An interview with the authors of Did AIM-HIGH aim too low. Interview by Jinghong Xu. J Diabetes. 2012 Mar; 4(1):3.
An interview with the authors of Did AIM-HIGH aim too low. Interview by Jinghong Xu.
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary. Endocr Pract. 2012 Mar-Apr; 18(2):269-93.
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary.
Rosenstock J, Hernandez-Triana E, Handelsman Y, Misir S, Jones MR, Nagendran S
Initial combination therapy with metformin plus colesevelam in drug-na?ve Hispanic patients with early type 2 diabetes. Postgrad Med. 2012 Jul; 124(4):7-13.
Initial combination therapy with metformin plus colesevelam in drug-na?ve Hispanic patients with early type 2 diabetes.
Rosenstock J, Hernandez-Triana E, Handelsman Y, Misir S, Jones MR
Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes. Postgrad Med. 2012 Jul; 124(4):14-20.
Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes.
Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, Endahl L, Mathieu C, NN1250-3579 (BEGIN Once Long) Trial Investigators
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012 Dec; 35(12):2464-71.
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
McMahon MM, Hurley DL, Mechanick JI, Handelsman Y
American Association of Clinical Endocrinologists' position statement on clinical nutrition and health promotion in endocrinology. Endocr Pract. 2012 Sep-Oct; 18(5):633-41.
American Association of Clinical Endocrinologists' position statement on clinical nutrition and health promotion in endocrinology.
Mechanick JI, Garber AJ, Handelsman Y, Garvey WT
American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract. 2012 Sep-Oct; 18(5):642-8.
American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine.
Sugar-sweetened beverages: changing the tide. J Diabetes. 2013 Mar; 5(1):1-2.
Sugar-sweetened beverages: changing the tide.
Garber AJ, Blonde L, Bloomgarden ZT, Handelsman Y, Dagogo-Jack S
The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract. 2013 Jan-Feb; 19(1):100-6.
The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations.
Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, Garber AJ, Garg A, Garvey WT, Grunberger G, Henry RR, Lavin N, Tapiador CD, Weyer C, American Association of Clinical Endocrinologists
The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013 Jan-Feb; 19(1):107-16.
The clinical approach to the detection of lipodystrophy - an AACE consensus statement.
Bloomgarden ZT, Drexler A, Einhorn D, Grunberger G, Guan Y, Handelsman Y, Hu JC, Li X, Liu J, Wang W, Weng J, Ning G
The Journal of diabetes: continuing the dialogue. J Diabetes. 2013 Jun; 5(2):95-6.
The Journal of diabetes: continuing the dialogue.
Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skj?th TV, Rana A, Mathieu C, BEGIN Once Long trial investigators
Diabetic medicine : a journal of the British Diabetic Association
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type?2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013 Nov; 30(11):1298-304.
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type?2 diabetes: a 2-year randomized, treat-to-target trial.
Handelsman Y, Leroith D, Bloomgarden ZT, Dagogo-Jack S, Einhorn D, Garber AJ, Grunberger G, Harrell RM, Gagel RF, Lebovitz HE, McGill JB, Hennekens CH
Diabetes and cancer--an AACE/ACE consensus statement. Endocr Pract. 2013 Jul-Aug; 19(4):675-93.
Diabetes and cancer--an AACE/ACE consensus statement.
Rodbard HW, Gough S, Lane W, Korsholm L, Bretler DM, Handelsman Y
Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials. Endocr Pract. 2014 Apr; 20(4):285-92.
Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.
Lessons from glargine trials: what is the goal fasting glucose with basal insulin? J Diabetes. 2014 Jul; 6(4):271-3.
Lessons from glargine trials: what is the goal fasting glucose with basal insulin?
Gregory RS, Handelsman Y, Pezalla EJ, Pikelny D
Practical perspectives on the management of overweight and obesity. Am J Manag Care. 2014 Mar; 20(3 Suppl):S64-75.
Practical perspectives on the management of overweight and obesity.
Grunberger G, Abelseth JM, Bailey TS, Bode BW, Handelsman Y, Hellman R, Jovanovic L, Lane WS, Raskin P, Tamborlane WV, Rothermel C
Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endocr Pract. 2014 May; 20(5):463-89.
Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force.
Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G
American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive action. Endocr Pract. 2014 Sep; 20(9):956-76.
American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive action.
Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G, The Aace Obesity Scientific Committee
American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014 Sep; 20(9):977-89.
American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease.
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH
AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015 Apr; 21(4):438-47.
AACE/ACE comprehensive diabetes management algorithm 2015.
Grunberger G, Bailey T, Camacho PM, Einhorn D, Garber AJ, Handelsman Y, Harrell RM, Lando HM, Law B, Leffert JD, Orzeck EA, Glucose Monitoring Consensus Conference Writing Committee
Proceedings from the American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on glucose monitoring. Endocr Pract. 2015 May; 21(5):522-33.
Proceedings from the American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on glucose monitoring.
Einhorn D, Handelsman Y, Bode BW, Endahl LA, Mersebach H, King AB
PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS. Endocr Pract. 2015 Aug; 21(8):917-26.
PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS.
POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS. Endocr Pract. 2015 Sep; 21(9):1054-65.
POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT? Endocr Pract. 2015 Dec; 21(12):1442-4.
SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE, American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract. 2015 Dec; 21(12):1403-14.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY.
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE, American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocr Pract. 2016 Jan; 22(1):84-113.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.
Mechanick JI, Harrell RM, Allende-Vigo MZ, Alvayero C, Arita-Melzer O, Aschner P, Camacho PM, Castillo RZ, Cerdas S, Coutinho WF, Davidson JA, Garber JR, Garvey WT, Gonz?lez FJ, Granados DO, Hamdy O, Handelsman Y, Jim?nez-Navarrete MF, Lupo MA, Mendoza EJ, Jim?nez-Montero JG, Zangeneh F, American Association of Clinical Endocrinologists (AACE), American College of ENdocrinology (ACE)
TRANSCULTURALIZATION RECOMMENDATIONS FOR DEVELOPING LATIN AMERICAN CLINICAL PRACTICE ALGORITHMS IN ENDOCRINOLOGY--PROCEEDINGS OF THE 2015 PAN-AMERICAN WORKSHOP BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016 Apr; 22(4):476-501.
TRANSCULTURALIZATION RECOMMENDATIONS FOR DEVELOPING LATIN AMERICAN CLINICAL PRACTICE ALGORITHMS IN ENDOCRINOLOGY--PROCEEDINGS OF THE 2015 PAN-AMERICAN WORKSHOP BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY.
Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract. 2016 Jun; 22(6):753-62.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.
Handelsman Y, Fain R, Wang Z, Li X, Fujioka K, Shanahan W
Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with =5% weight loss. Postgrad Med. 2016 Nov; 128(8):740-746.
Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with =5% weight loss.
Bloomgarden Z, Mende C, Einhorn D, Handelsman Y
Diabetes treatment over age 65: Is worse control really better? J Diabetes. 2017 May; 9(5):428-430.
Diabetes treatment over age 65: Is worse control really better?
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M, Zangeneh F, Bush MA
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com. Endocr Pract. 2017 Apr 02; 23(4):479-497.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com.
Leiter LA, Zamorano JL, Bujas-Bobanovic M, Louie MJ, Lecorps G, Cannon CP, Handelsman Y
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017 07; 19(7):989-996.
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.
Is HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old? Diabetes Care. 2017 04; 40(4):526-528.
Is HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old?
JCL roundtable: Future of the lipid laboratory: Using the laboratory to manage the patient (part 2). J Clin Lipidol. 2017 Jul - Aug; 11(4):846-854.
JCL roundtable: Future of the lipid laboratory: Using the laboratory to manage the patient (part 2).
Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017 Jul 04; 318(1):45-56.
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Bloomgarden ZT, Kosiborod MN, Handelsman Y
Concomitant Diabetes and Atrial?Fibrillation: No Sugarcoating the Bittersweet Reality. J Am Coll Cardiol. 2017 09 12; 70(11):1336-1338.
Concomitant Diabetes and Atrial?Fibrillation: No Sugarcoating the Bittersweet Reality.
Vinik AI, Camacho PM, Davidson JA, Handelsman Y, Lando HM, Leddy AL, Reddy SK, Cook R, Spallone V, Tesfaye S, Ziegler D, Task Force to Develop an AACE Position Statement on Autonomic Testing
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON TESTING FOR AUTONOMIC AND SOMATIC NERVE DYSFUNCTION. Endocr Pract. 2017 Dec; 23(12):1472-1478.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON TESTING FOR AUTONOMIC AND SOMATIC NERVE DYSFUNCTION.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. Endocr Pract. 2018 01; 24(1):91-120.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Grunberger G, Handelsman Y, Bloomgarden ZT, Fonseca VA, Garber AJ, Haas RA, Roberts VL, Umpierrez GE
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2018 POSITION STATEMENT ON INTEGRATION OF INSULIN PUMPS AND CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH DIABETES MELLITUS. Endocr Pract. 2018 Mar; 24(3):302-308.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2018 POSITION STATEMENT ON INTEGRATION OF INSULIN PUMPS AND CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH DIABETES MELLITUS.
Journal of the American Heart Association
PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. J Am Heart Assoc. 2018 06 22; 7(13).
PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review.
World congress on insulin resistance, diabetes and cardiovascular disease. J Diabetes. 2018 Oct; 10(10):776-777.
World congress on insulin resistance, diabetes and cardiovascular disease.
Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, Meier JJ
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100?U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018 12; 20(12):2821-2829.
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100?U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
Lingvay I, Handelsman Y, Linjawi S, Vilsb?ll T, Halladin N, Ranc K, Liebl A
EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2019 Feb; 25(2):144-155.
EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.
Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019 04; 21(4):883-892.
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Notes from the world congress on insulin resistance, diabetes, and cardiovascular disease. J Diabetes. 2019 Apr; 11(4):258-260.
Notes from the world congress on insulin resistance, diabetes, and cardiovascular disease.
Handelsman Y, Chovanes C, Dex T, Giorgino F, Skolnik N, Souhami E, Stager W, Niemoeller E, Frias JP
Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. J Diabetes Complications. 2019 03; 33(3):236-242.
Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.
Bloomgarden Z, Einhorn D, Grunberger G, Handelsman Y
Fournier's gangrene and sodium-glucose cotransporter 2 inhibitors: Is there a causal association? J Diabetes. 2019 05; 11(5):340-341.
Fournier's gangrene and sodium-glucose cotransporter 2 inhibitors: Is there a causal association?
Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML, Elliott-Davey M, Somaratne R, Reaven P
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. Diabetologia. 2019 06; 62(6):948-958.
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.
Gerald Reaven: A man for our times. Diab Vasc Dis Res. 2019 03; 16(2):113-115.
Introduction to the 2nd Heart in Diabetes (HiD) Meeting. J Diabetes. 2019 07; 11(7):599-600.
Introduction to the 2nd Heart in Diabetes (HiD) Meeting.
Tomaszewski KJ, Allen A, Mocarski M, Schiffman A, Kruger D, Handelsman Y, Heile M, Brod M
Divergence in perceptions of diabetes control among patients with type 2 diabetes mellitus treated with basal insulin and health care professionals: results from the US Perceptions of Control (POC-US) study. Patient Prefer Adherence. 2019; 13:761-773.
Divergence in perceptions of diabetes control among patients with type 2 diabetes mellitus treated with basal insulin and health care professionals: results from the US Perceptions of Control (POC-US) study.
Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. Adv Ther. 2019 12; 36(12):3321-3339.
Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.
Butler J, Handelsman Y, Bakris G, Verma S
Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur J Heart Fail. 2020 04; 22(4):604-617.
Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, Blonde L, Bush MA, DeFronzo RA, Garber JR, Garvey WT, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Perreault L, Rosenblit PD, Samson S, Umpierrez GE
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020 01; 26(1):107-139.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Paradigm shift in the management of DM & CVD-preventing the next CV event. J Diabetes. 2020 Sep; 12(9):630-632.
Paradigm shift in the management of DM & CVD-preventing the next CV event.
Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, Handelsman Y, Verma S, Anker SD, McMurray JJV, Kosiborod MN, Butler J
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. Circulation. 2020 09 22; 142(12):1205-1218.
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. Vasc Health Risk Manag. 2020; 16:403-418.
Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
American journal of preventive cardiology
Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC. Am J Prev Cardiol. 2020 Mar; 1:100007.
Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC.
Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
Miller M, Tokgozoglu L, Parhofer KG, Handelsman Y, Leiter LA, Landmesser U, Brinton EA, Catapano AL
Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Expert Rev Cardiovasc Ther. 2022 Aug; 20(8):609-625.
Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
DCRM Multispecialty Recommendations in Patients With Heart Failure. J Card Fail. 2022 11; 28(11):1642-1645.
DCRM Multispecialty Recommendations in Patients With Heart Failure.
Handelsman Y, Butler J, Bakris GL, DeFronzo RA, Fonarow GC, Green JB, Grunberger G, Januzzi JL, Klein S, Kushner PR, McGuire DK, Michos ED, Morales J, Pratley RE, Weir MR, Wright E, Fonseca VA
Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2023 02; 37(2):108389.
Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases.
Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2023 07 11; 82(2):161-170.
Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week.
Ibrahim M, Ba-Essa EM, Baker J, Cahn A, Ceriello A, Cosentino F, Davies MJ, Eckel RH, Van Gaal L, Gaede P, Handelsman Y, Klein S, Leslie RD, Pozzilli P, Del Prato S, Prattichizzo F, Schnell O, Seferovic PM, Standl E, Thomas A, Tuomilehto J, Valensi P, Umpierrez GE
Diabetes/metabolism research and reviews
Cardio-renal-metabolic disease in primary care setting. Diabetes Metab Res Rev. 2024 Mar; 40(3):e3755.
Cardio-renal-metabolic disease in primary care setting.
Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Cherney DZI, DeFronzo RA, Del Prato S, Eckel RH, Filippatos G, Fonarow GC, Fonseca VA, Garvey WT, Giorgino F, Grant PJ, Green JB, Greene SJ, Groop PH, Grunberger G, Jastreboff AM, Jellinger PS, Khunti K, Klein S, Kosiborod MN, Kushner P, Leiter LA, Lepor NE, Mantzoros CS, Mathieu C, Mende CW, Michos ED, Morales J, Plutzky J, Pratley RE, Ray KK, Rossing P, Sattar N, Schwarz PEH, Standl E, Steg PG, Tokg?zoglu L, Tuomilehto J, Umpierrez GE, Valensi P, Weir MR, Wilding J, Wright EE
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024 Oct; 159:155931.
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
Christofides EA, Stankiewicz A, Denham D, Bellido D, Franek E, Nakhle S, Lukaszewicz M, Reed J, C?zar-Le?n V, Kosch C, Karas P, Fitz-Patrick D, Handelsman Y, Warren M, Hollander P, Huffman D, Raskin P, Oroszl?n T, Lillestol M, Ovalle F
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26?Weeks Treatment. Endocr Pract. 2024 Sep; 30(9):810-816.
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26?Weeks Treatment.
Liu L, Ke W, Li H, Li F, Fan G, Kuang J, Ma J, Zhang X, Ji B, Li S, Du Y, Xue Y, Lyu Z, Gao L, Qu S, Shi Y, Yan L, Deng W, Xu C, Dai P, Xu L, Liu J, Wan X, Wei G, Yu S, Hong S, Zhang P, Huang Z, Cao X, Liao Z, Xiao H, Mu Y, Handelsman Y, Li Y
Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial. BMJ. 2024 10 15; 387:e080122.
Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.
Buse JB, Kahn SE, Aroda VR, Auchus RJ, Bailey T, Bancos I, Busch RS, Christofides EA, DeFronzo RA, Eilerman B, Findling JW, Fonseca V, Hamidi O, Handelsman Y, Miller HJ, Ownby JG, Parker JC, Philis-Tsimikas A, Pratley R, Rosenstock J, Shanik MH, Sloan LL, Umpierrez G, Tudor IC, Schlafly TK, Einhorn D, CATALYST Investigators
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care. 2025 Apr 18.
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.
Lazarus JV, White TM, Allen AM, Pannain S, Alkhouri N, Bansal MB, Charlton M, Fortune BE, Handelsman Y, Isaacs S, Jacobson IM, Kumar S, Manolas MI, Noureddin M, Rinella ME, Terrault N, El-Mohandes A
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United States. Hepatol Commun. 2025 May 01; 9(5).
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United States.
Use of finerenone in patients with chronic kidney disease at high risk of heart failure. Metabolism. 2025 Aug; 169:156297.
Use of finerenone in patients with chronic kidney disease at high risk of heart failure.
Kang YM, Giugliano RP, Ran X, Deedwania P, De Ferrari GM, George JT, Gouni-Berthold I, Paiva da Silva Lima G, Handelsman Y, Lewis BS, Ohman EM, Wang H, L?pez JAG, Monsalvo ML, Sabatine MS, Leiter LA
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. Diabetes Care. 2025 Sep 01; 48(9):1512-1516.
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial.
DeFronzo RA, Fonseca V, Aroda VR, Auchus RJ, Bailey T, Bancos I, Busch RS, Buse JB, Christofides EA, Eilerman B, Findling JW, Handelsman Y, Kahn SE, Miller HJ, Ownby JG, Parker JC, Philis-Tsimikas A, Pratley R, Rosenstock J, Shanik MH, Sloan LA, Umpierrez G, Shambharkar S, Tudor IC, Schlafly TK, Einhorn D, CATALYST Investigators
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. Diabetes Care. 2025 Jun 23.
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.